This study aims to assess the effect and safety of the traditional Mongolian medicine Anshen Buxin Liuwei Pill for the treatment of cardiac neurosis.

Cardiac neurosis is a group of symptoms characterized by the coexistence of cardiovascular disease related symptoms and nervous system disorders. Anshen Buxin Liuwei Pill is a kind of traditional Mongolian medicine for the treatment of cardiac neurosis. This study aims to evaluate the effect and safety of Anshen Buxin Liuwei Pill for cardiac neurosis in a prospective, randomized, double-blind, placebo-controlled clinical trial.

Inclusion Criteria:

• Age ≥18 years old, ≤75 years old;
• Meet the diagnostic criteria for cardiac neurosis: the patient has palpitations, precordial pain, chest tightness, shortness of breath, dyspnea, dizziness, insomnia and dreaminess, cold hands and feet, hyperhidrosis and other cardiovascular symptoms and neurological disorders;
• Meet the diagnostic criteria of Heyisheng type palpitations in Mongolian medicine;
• There is no objective diagnosis of coronary heart disease (in accordance with any of the following): ①The activity flat test is negative; ② Coronary angiography or coronary CTA suggests that the lumen stenosis is ≤50%; ③ Exercise or drug load radionuclide examination results suggest no myocardial ischemia;
• The patient did not take anti-anxiety and depression drugs or psychotropic drugs within 2 weeks before enrollment;
• agrees to voluntarily participate in the study and signs an informed consent form .

Exclusion Criteria:

• Accompanied by organic heart disease, severe cardiopulmonary insufficiency;
• Poor hypertension control (systolic blood pressure ≥160mmHg or diastolic blood pressure ≥100mmHg after treatment);
• Those with malignant arrhythmia;
• Those who use pacemakers;
• Patients with hyperthyroidism;
• Combined with severe liver and kidney damage (ALT, AST or TBIL> 2 times the upper limit of the normal reference value, or Cr> 1.5 times the upper limit of the normal reference value);
• People with serious primary diseases such as hematopoietic system or mental illness;
• SAS≥70;
• SDS≥73;
• Accompanying any other serious diseases or conditions such as malignant tumors;
• Women during pregnancy and lactation;
• People with allergies or allergies to the known ingredients of the research drug;
• Participated in other clinical research in the past 3 months;
• According to the judgment of the investigator, the subject is not suitable for research observation.